The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.
作者信息
Ndonwi M, Girard T J, Broze G J
出版信息
J Thromb Haemost. 2012 Sep;10(9):1944-6. doi: 10.1111/j.1538-7836.2012.04834.x.
Abstract
摘要
相似文献
1
The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.
J Thromb Haemost. 2012 Sep;10(9):1944-6. doi: 10.1111/j.1538-7836.2012.04834.x.
2
Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα.
Thromb Haemost. 2020 Jan;120(1):55-64. doi: 10.1055/s-0039-1700516. Epub 2019 Nov 8.
3
Role of the acidic hirudin-like COOH-terminal amino acid region of factor Va heavy chain in the enhanced function of prothrombinase.
Biochemistry. 2008 Jul 29;47(30):7963-74. doi: 10.1021/bi800593k. Epub 2008 Jul 1.
4
The critical role of the 185-189-loop in the factor Xa interaction with Na+ and factor Va in the prothrombinase complex.
J Biol Chem. 2004 Nov 12;279(46):48262-9. doi: 10.1074/jbc.M409964200. Epub 2004 Sep 3.
5
Factor V.
Methods Enzymol. 1993;222:224-36. doi: 10.1016/0076-6879(93)22016-9.
6
Influence of factor V and factor Va on APC-induced cleavage of human factor VIII.
Thromb Haemost. 1995 Apr;73(4):730-1.
7
The contribution of amino acid region ASP695-TYR698 of factor V to procofactor activation and factor Va function.
J Biol Chem. 2004 Jan 23;279(4):3084-95. doi: 10.1074/jbc.M306850200. Epub 2003 Oct 14.
8
The mechanism of inactivation of human factor V and human factor Va by activated protein C.
J Biol Chem. 1994 Dec 16;269(50):31869-80.
9
Demonstration of exosite I-dependent interactions of thrombin with human factor V and factor Va involving the factor Va heavy chain: analysis by affinity chromatography employing a novel method for active-site-selective immobilization of serine proteinases.
Biochemistry. 1998 Sep 22;37(38):13143-52. doi: 10.1021/bi9812165.
10
Role of regulatory exosite I in binding of thrombin to human factor V, factor Va, factor Va subunits, and activation fragments.
J Biol Chem. 1999 Jun 25;274(26):18635-43. doi: 10.1074/jbc.274.26.18635.
引用本文的文献
1
A hydrophobic patch (PLVIVG; 1481-1486) in the B-domain of factor V-short is crucial for its synergistic TFPIα-cofactor activity with protein S and for the formation of the FXa-inhibitory complex comprising FV-short, TFPIα, and protein S.
J Thromb Haemost. 2022 May;20(5):1146-1157. doi: 10.1111/jth.15690. Epub 2022 Mar 16.
2
The contribution of TFPIα to the hemostatic response to injury in mice.
J Thromb Haemost. 2021 Sep;19(9):2182-2192. doi: 10.1111/jth.15430. Epub 2021 Jul 14.
3
Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.
J Biol Chem. 2021 Jan-Jun;296:100234. doi: 10.1074/jbc.RA120.016341. Epub 2021 Jan 7.
4
Platelet-Derived Factor V Is an Important Determinant of the Metastatic Potential of Circulating Tumor Cells.
Front Oncol. 2020 Sep 23;10:558306. doi: 10.3389/fonc.2020.558306. eCollection 2020.
5
Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia.
Haemophilia. 2019 Nov;25(6):1083-1091. doi: 10.1111/hae.13860. Epub 2019 Oct 14.
6
Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors.
Res Pract Thromb Haemost. 2017 Dec 20;2(1):114-124. doi: 10.1002/rth2.12057. eCollection 2018 Jan.
7
TFPIα interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation.
Blood Adv. 2017 Dec 26;1(27):2692-2702. doi: 10.1182/bloodadvances.2017011098.
8
Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
Br J Clin Pharmacol. 2018 Jan;84(1):79-87. doi: 10.1111/bcp.13429. Epub 2017 Oct 18.
9
10
Reduced Prothrombinase Inhibition by Tissue Factor Pathway Inhibitor Contributes to the Factor V Leiden Hypercoagulable State.
Blood Adv. 2017 Feb 14;1(6):386-395. doi: 10.1182/bloodadvances.2016002295.
本文引用的文献
1
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.
Blood. 2008 Nov 1;112(9):3615-23. doi: 10.1182/blood-2008-06-162453. Epub 2008 Aug 11.
2
Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI.
Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):802-8. doi: 10.1161/01.atv.16.6.802.
3
Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a).
Arterioscler Thromb. 1993 Jul;13(7):1066-75. doi: 10.1161/01.atv.13.7.1066.
4
Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
Blood Coagul Fibrinolysis. 1993 Oct;4(5):661-9.
5
Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli.
Thromb Haemost. 1994 Mar;71(3):339-46.
6
Heterogeneity of plasma tissue factor pathway inhibitor.
Blood Coagul Fibrinolysis. 1994 Aug;5(4):551-9.
7
8
Identification of the 1.4 kb and 4.0 kb messages for the lipoprotein associated coagulation inhibitor and expression of the encoded protein.
Thromb Res. 1989 Jul 1;55(1):37-50. doi: 10.1016/0049-3848(89)90454-4.
9
Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.
Blood. 1992 Apr 15;79(8):2004-10.
Zotero 插件